Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,156 GBX | -0.12% | +7.88% | +14.68% |
05:18pm | AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial | MT |
04:46pm | AstraZeneca: research into respiratory diseases | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The firm trades with high earnings multiples: 22.43 times its 2024 earnings per share.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.68% | 236B | B+ | ||
+30.22% | 699B | C+ | ||
+25.07% | 571B | B | ||
-4.66% | 364B | C+ | ||
+18.37% | 326B | B- | ||
+2.87% | 286B | C+ | ||
+4.71% | 198B | B- | ||
-12.43% | 194B | A+ | ||
-3.32% | 154B | C+ | ||
-4.26% | 149B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AZN Stock
- Ratings AstraZeneca PLC